Biotechnology company developing next-generation targeted biologics for migraine prevention
Biotechnology company developing next-generation targeted biologics for migraine prevention. Its pipeline includes anti-PACAP monoclonal antibodies and a PACAP/CGRP bispecific antibody, designed to address patients who do not respond adequately to existing migraine therapies. The programs are preclinical and incorporate antibody engineering and half-life extension intended to enable infrequent subcutaneous dosing.